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AIMS OF THE STUDY 
 
 
 
 
1. To determine the incidence of isolated ipsilateral 
supraclavicular nodal metastases at presentation, in 
patients with carcinoma breast. 
 
2. To study the outcomes in response rates, disease free 
survival, overall survival in patients with carcinoma breast 
who presented with ipsilateral supraclavicular nodal 
metastases. 
 
3. To determine the factors affecting the disease free 
survival (DFS) and overall survival (OS). 
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BACKGROUND 
 
 
 
 
The female breast has been an organ of fascination and so 
also the treatment of breast cancer. The treatment of breast 
cancer has remained an enigma from the ancient past to present 
day .Tremendous progress has been made in the management of 
carcinoma breast. Despite this, the treatment is still a complex 
issue. Breast cancer is a major public health problem for 
women throughout the world. In India, breast cancer remains 
the most common cancer in urban women.  
 
Since 1990, the death rate from breast cancer has 
decreased in the United States by 24% and similar reductions 
have been observed in other developed countries.1,2 
Mathematical models suggest that both the adoption of 
screening mammography and the availability of adjuvant 
chemotherapy and tamoxifen have contributed approximately 
equally to this improvement.3 Although breast cancer has 
traditionally been less common in non industrialized nations, its 
incidence in these areas is increasing. Multiple factors are 
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associated with an increased risk of developing breast cancer, 
including increasing age, family history, exposure to female 
reproductive hormones (both endogenous and exogenous), 
dietary factors, benign breast disease, and environmental 
factors. 
        
Invasive breast cancers constitute a heterogeneous group 
of lesions that differ with regard to their clinical presentation, 
radiographic characteristics, pathologic features, and biologic 
behavior. The most common histologic type of invasive breast 
cancer is invasive (infiltrating) ductal carcinoma. The most 
widely used histologic grading is that proposed by Elston and 
Ellis and is a modification of the grading system proposed by 
Bloom and Richardson. It is based on tubule formation, nuclear 
pleomorphism, and mitotic activity.4 Patients are staged 
according to The American Joint Committee on Cancer (AJCC) 
TNM staging system, 2009. 
 
The patients are broadly divided into three groups for the 
purpose of management. Early breast cancer (EBC), Locally 
advanced breast cancer (LABC) and Metastatic breast cancer 
(MBC). Though the incidence of early breast cancer is rising in 
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the developed countries, in India many patients still present 
with locally advanced breast cancer.  
 
Patients with LABC include those with  
1. operable disease at presentation (clinical stage T3N1),  
2. inoperable disease at presentation (clinical stage T4 
and/or N2-N3)  
3. inflammatory breast cancer (clinical stage T4dN0-3). 
 
Patients with LABC should be managed by a 
multidisciplinary team. Treatment typically includes 
neoadjuvant chemotherapy, surgery, and radiation therapy. The 
vast majority of patients will have clinical response to therapy.  
Prior to the use of neoadjuvant chemotherapy, long-term 
survival was uncommon. Long-term survival has been greatly 
improved with aggressive trimodality treatment. Only about 
10% of patient’s have metastatic disease at presentation.  
 
The subset of patients who have isolated ipsilateral 
supraclavicular lymph nodal metastases at presentation with no 
other evidence of distant metastases constitutes about 1% of 
patients who present with carcinoma breast.5 These patients 
who were previously classified under stage IV, are now 
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classified in stage IIIC, since their survival is almost equivalent 
to that of stage IIIB. Patients in this subset should not be under 
treated and there is still a possibility of cure.6 There are no 
standard guidelines of treatment for this group of patients. 
 
There is very little evidence regarding the management of 
these patients, especially in Indian literature.  Hence we decided 
to study patients who were treated at our institute, with 
ipsilateral supraclavicular nodal metastases at diagnosis and 
with no other evidence of distant metastases.  
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MATERIALS  AND  METHODS 
 
 
 
A retrospective study of patients who presented with 
carcinoma breast, treated at Cancer Institute (WIA) from the 
year 2000 to 2008 was done. The total number of patients who 
were diagnosed to have invasive cancer of the breast, during the 
study period was 5587. Of the 5587 patients, we identified 60 
patients who presented with ipsilateral supraclavicular lymph 
nodal metastases but no evidence of other distant metastases. 
 
Patients with distant metastases other than ipsilateral 
supraclavicular metastases were excluded. Patients with 
bilateral breast cancers were also excluded. All patients 
underwent biopsies of the breast tumor, to document invasive 
carcinoma. Pretreatment evaluation consisted of a thorough 
history, clinical examination, contralateral mammogram, 
staging workup that included a chest x-ray, nuclear bone scan, 
ultrasound of the abdomen and pelvis. All 60 patients had 
metastatic supraclavicular node, diagnosed either by a fine 
needle aspiration cytology or an excision biopsy of the lymph 
node. 
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Each patient was evaluated in a multidisciplinary planning 
clinic before therapy was initiated. The clinical team included a 
surgical oncologist, a medical oncologist, along with a radiation 
oncologist  and  was supported by a breast radiologist. 
 
After obtaining an informed consent, treatment was 
initiated. Most patients were treated with concurrent 
chemotherapy and radiotherapy. On day 1 of treatment, patients 
received the specified regimen of chemotherapy followed by 
initiation of radiation to the breast, axilla and supraclavicular 
region from day 2.  Radiotherapy consisted of external beam 
radiotherapy to the involved breast, axilla and the 
supraclavicular region to a total dose of 40 Gy in 4 weeks, 
usually in fractions of 2 Gy daily and 5 fractions per week.  The 
fields used were medial and lateral tangential fields with 
acceptable dose to the lungs and heart. 
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The chemotherapeutic regimens were FAC, FEC, CMF 
and TE. 
DRUG DOSE 
Adriamycin 40 mg/m2 
Methotrexate 60 mg/m2 
5 Fluoro-uracil 600 mg/m2 
Cyclophosphamide 600 mg/m2 
Paclitaxel 175 mg/m2 
 
Response of the primary and regional nodes were noted at 
the completion of chemoradiotherapy. Anti-estrogens were 
started according to their estrogen and progesterone receptor 
status. These patients were followed up in a 3 monthly interval 
with clinical examination. All patients underwent metastatic 
workup annually. Some patients underwent surgery. 
 
Patient’s who relapsed were identified and appropriate 
treatment was given. Recurrence patterns on follow up were 
also noted.  Follow up of these patients was updated till March 
2011 or till their death. Patients who had defaulted during 
treatment or refused further treatment were also noted.  
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Statistical analysis was done using Pearson’s chi-square 
test for univariate analysis and multinominal logistic regression 
analysis for multivariate analysis. Survival was calculated using 
life-tables analysis and various factors influencing survival 
were compared using Cox Regression analysis. All statistical 
analysis was done using SPSS for Windows version 14. 
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REVIEW OF LITERATURE 
 
 
 
 
Breast cancer is the most common cancer among women 
in India.7 The incidence of breast cancer too has shown a steady 
increase in the past few decades. The current Crude incidence 
rate (CIR) of breast cancer in the MMTR (Madras Metropolitan 
Tumor Registry) is 30.2. 
 
The crude incidence rates of breast cancer has steadily 
risen from 14.3 in the year 1982, which is the year of starting 
the Madras Metropolitan Tumor Registry (MMTR) at the 
Cancer Institute, to 30.2 in the year 2008. It is seen that the 
incidence amongst the urban Indian women is higher than in the 
rural population. Among the metropolitan cities, the incidence 
is highest in Chennai followed Mumbai, Delhi and Bangalore. 
In our country we are seeing a rise in the incidence of disease in 
the younger age groups i.e, less than 40 years. In the US and 
UK the percentage of breast cancers in women less than 40 
years is around 6% whereas in our country it is as high as 23%. 
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Conversely the proportion of older women with the disease is 
45% in the affluent countries while it is only 20%.8 
 
The receptor status – Estrogen(ER) and Progesterone(PR), 
is one of the most important predictive factors in breast cancer.  
use of hormonal agents like Tamoxifen, Aromatase inhibitors 
and a host of other drugs is determined by the expression of the 
hormonal receptors by the breast tumors. There was an excess 
of receptor negative women in our population both in the 
premenopausal and the postmenopausal woman.  
 
In the MMTR data, there was a steady increase in the 
Crude incidence rates with rising educational levels. The CIR 
was 8 in illiterate women, compared to 40 among literate 
women. The incidence of the disease was highest among high 
income groups as compared to low and middle income groups. 
In our own city as per the MMTR statistics available, stages II 
and III cancers account for 55% with a mere 1% in stage I 
cancer. This is in contradiction to the western population where 
the incidence of stage I cancer accounted for 60%.9 
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EVOLUTION OF TREATMENT 
 
The study of history of treatment of breast cancer dates 
back to the era of Galen (130 – 200 AD), when it was believed 
that cancer is a result of “black bile” and the treatment therefore 
was to let out the bile. In the end of 19th century after the advent 
of anaesthesia and antisepsis, surgery became the main stay of 
treatment. 
 
The treatment evolved as the understanding of the disease 
biology improved. According to the Halsteadian concept, put 
forth by Sir William Halstead in 1890, breast cancer is a 
localized disease in the initial stages and there is a predictable , 
orderly spread of the disease from the breast to the regional 
nodes and then to the systemic circulation.10 Hence treatment in 
the Halsteadian era was Radical en bloc mastectomy and it was 
believed that more radical the surgery, better the survival. This 
formed the basis for the era of Radical, Ultra Radical and 
Extended mastectomy. 
 
In 1980, Bernard Fischer put forth his theory that breast 
cancer is a systemic disease right from it’s inception. The 
treatment needs to be therefore directed to systemic therapy.11 
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In 1994, Samuel Hellman put forth his theory of “ 
Spectrum Hypothesis”. This stated that breast cancer was a 
spectrum of diseases with one end of the spectrum being 
localized and on the other end was a systemic disease. Today 
we accept the spectrum theory and the treatment is thus aimed 
at the local and the systemic components according to the stage 
of the disease.12 
 
LYMPHATICS 
 
The subepithelial and the subdermal lymphatic plexus are 
confluent with the subareolar plexus, which in turn 
communicate with the fine lymphatics of the lactiferous ducts. 
Lymph flows unidirectionally in valvular lymphatics from the 
superficial to the deep and toward the regional lymph nodes. 
The lymph from the breast primarily drains into the axillary 
lymph nodes. They are divided into the central, apical, medial, 
lateral, anterior and posterior groups. Surgeons and pathologists 
group the axillary lymph nodes according to their relationship 
to the pectoralis minor muscle. Level I consists of nodes lateral 
to the pectoralis minor. Level II consists of nodes deep to the 
muscle and level III consists of nodes medial to this muscle. 
The internal mammary nodes are found in the second to sixth 
intercostal spaces at the sternal border.  
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As a consequence of obstruction to lymph flow by the 
neoplastic process, reversal of lymph flow is evident. Central 
and medial lymphatic of the breast pass medially, perforate the 
pectoralis major muscle and thereafter terminate in the internal 
mammary nodal chain. The right internal mammary nodal 
group enters the right lymphatic duct and the left enters the 
main thoracic duct. The presence of supraclavicular lymph 
nodes results from lymphatic permeation and subsequent 
obstruction of the deep cervical nodes of the jugular subclavian 
confluence.13 
 
Gross communications from the interstices of the 
connecting lymphatics from each breast provides ready access 
to the lymphatic flow to the contralateral axilla and the breast. 
This explains the occasional metastatic involvement of opposite 
axillary nodes. 
 
According to the AJCC Staging System for Breast 
Cancer, nodal metastases located in the supraclavicular fossa 
are staged as loco-regional metastases (N3c). Lymph node 
metastases situated above the supraclavicular region are not 
mentioned, but should be considered as distant metastases.14 
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PROGNOSTIC FACTORS 
 
A prognostic factor is one which at the time of diagnosis 
or surgery is associated with outcome – overall survival, 
disease free survival. The prognostic factors include axillary 
nodal status, tumor size, grade, age, menopausal status, receptor 
status, presence of lymphovascular invasion, cerbB2. The 
axillary lymph nodal status is still the most important factor that 
affects the prognosis. The probability of recurrence is higher for 
women with histologically positive axillary lymph nodes and 
increases with each additional lymph node. Axillary lymph 
node dissection provides prognostic information, but has 
minimal therapeutic benefit or none, especially in women with 
clinically negative axillary lymph nodes and is responsible for 
the morbidity associated with breast surgery. 
 
PREDICTIVE FACTORS 
 
A predictive factor is one that helps make treatment 
decisions, particularly with regards to a choice of drug or 
modality of treatment. The most important predictive factor is 
the receptor status – ER/PR and the cerbB2 status. 
. 
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AJCC TNM STAGING 2009 
 
PRIMARY TUMOR (T) 
 
TX : Primary tumor cannot be assessed 
 
T0 : No evidence of primary tumor 
 
Tis : Intraductal carcinoma, lobular carcinoma in situ, or 
  Paget's disease of the nipple with no associated  
  invasion of normal breast tissue 
 Tis (DCIS): Ductal carcinoma in situ 
 Tis (LCIS): Lobular carcinoma in situ 
 Tis (Paget's): Paget's disease of the nipple with no tumor.  
 
T1: Tumor not larger than 2.0 cm in greatest dimension 
 T1mic: Microinvasion not larger than 0.1 cm in  
   greatest dimension 
 T1a:  Tumor larger than 0.1 cm but not larger than 
   0.5 cm in greatest dimension 
 T1b:  Tumor larger than 0.5 cm but not larger than 
   1.0 cm in greatest dimension 
 T1c:  Tumor larger than 1.0 cm but not larger than 
   2.0 cm in greatest dimension 
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T2: Tumor larger than 2.0 cm but not larger than 5.0 cm in 
 greatest dimension 
T3: Tumor larger than 5.0 cm in greatest dimension 
T4: Tumor of any size with direct extension to  
 (a) chest wall or (b) skin, only as described below 
 
 T4a: Extension to chest wall, not including pectoralis  
  muscle 
 T4b: Edema (including peau d'orange) or ulceration of the 
  skin of the breast, or satellite skin nodules confined 
  to the same breast 
 T4c: Both T4a and T4b 
 T4d: Inflammatory carcinoma 
 
REGIONAL LYMPH NODES (N) 
 
NX: Regional lymph nodes cannot be assessed (e.g., 
 previously removed) 
N0: No regional lymph node metastasis 
N1: Metastasis to movable ipsilateral axillary lymph node(s) 
N2: Metastasis to ipsilateral axillary lymph node(s) fixed or 
 matted, or in clinically apparenta ipsilateral internal 
 mammary nodes in the absence of clinically evident 
 lymph node metastasis 
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N2a: Metastasis in ipsilateral axillary lymph nodes fixed 
  to one another (matted) or to other structures 
 N2b: Metastasis only in clinically apparent ipsilateral  
  internal mammary nodes and in the absence of  
  clinically evident axillary lymph node metastasis 
N3: Metastasis in ipsilateral infraclavicular lymph node(s) 
 with or without axillary lymph node involvement, or in 
 clinically apparenta ipsilateral internal mammary lymph 
 node(s) and in the presence of clinically evident axillary 
 lymph node metastasis; or, metastasis in ipsilateral 
 supraclavicular lymph node(s) with or without axillary or 
 internal mammary lymph node involvement 
 N3a: Metastasis in ipsilateral infraclavicular lymph  
  node(s)    
 N3b: Metastasis in ipsilateral internal mammary lymph  
  node(s) and axillary lymph node(s) 
 N3c: Metastasis in ipsilateral supraclavicular lymph  
  node(s) 
 
DISTANT METASTASES (M) 
 
MX: Presence of distant metastases cannot be assessed 
M0: No distant metastases 
M1: Distant metastases 
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AJCC STAGE GROUPINGS 
 
Stage 0 Stage IIIA 
Tis, N0, M0 T0, N2, M0 
Stage I T1, N2, M0 
T1, N0, M0 T2, N2, M0 
Stage IIA T3, N1, M0 
T0, N1, M0 T3, N2, M0 
T1, N1, M0 Stage IIIB 
T2, N0, M0 T4, N0, M0 
Stage IIB T4, N1, M0 
T2, N1, M0 T4, N2, M0 
T3, N0, M0 Stage IIIC 
Any T, N3, M0 
Stage IV 
Any T, Any N, M1 
 
TREATMENT FOR BREAST CANCER: 
 
Surgery, radiotherapy and chemotherapy form the basic 
foundation for treating breast cancer patients. But newer 
modalities like targeted therapy and immunotherapy are joining 
a growing armamentarium of tools for therapy and support. 
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Surgery forms the mainstay of treatment for early breast cancer. 
In stage I and II, surgery forms initial treatment (modified 
radical mastectomy or breast conservation surgery), followed 
by adjuvant chemotherapy. In stage III, neoadjuvant therapy is 
used followed by mastectomy. Metastatic disease is treated with 
systemic therapy and local therapy being reserved for few 
situations. 
 
CRITERIA FOR INOPERABILITY (Haagenson)15 
 
1. Extensive edema of the skin over the breast is present. 
2. Satellite nodules are present in the skin over the breast. 
3. Intercostal or parasternal tumor nodules are present. 
4. Edema of the arm. 
5. Proven supraclavicular metastases are present. 
6. Inflammatory carcinoma. 
7. Distant metastases are demonstrated. 
8. When any two, or more, of the following signs of locally 
advanced carcinoma are present: 
a. Ulceration of the skin. 
b. Edema of the skin of limited extent (less than one-third 
of the skin over the breast involved). 
c. Fixation of the tumor to the chest wall. 
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d. Axillary lymph nodes measuring 2.5 cm, or more, in 
transverse diameter and proved to contain metastases 
by biopsy. 
e. Fixation of axillary lymph nodes to the skin or the deep 
structures 
 
ADJUVANT SYSTEMIC THERAPY 
 
 The goal of adjuvant systemic therapy is to prevent the 
recurrence of breast cancer by eradicating micrometastates that 
are present at the time of diagnosis. In current practice, three 
systemic treatment modalities are widely used as adjuvant 
therapy for early stage breast cancer. These modalities are (1) 
endocrine treatment such as tamoxifen, aromatase inhibitors or 
ovarian suppression, (2) anti-HER-2 therapy with the 
humanized monoclonal antibody trastuzumab and (3) 
chemotherapy. Selection of adjuvant treatment is determined by 
the biological features of the breast cancer. 
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Overview of Adjuvant Treatment Approaches in Breast 
Cancer 
Tumor HER Status 
Tumor Hormone-Receptor Status 
Positive Negative 
HER-2 negative/normalEndocrine therapy 
±chemotherapy 
Chemotherapy 
HER-2 
positive/overexpressed
Endocrine therapy + 
chemotherapy + 
trastuzumab 
Chemotherapy + 
trastuzumab 
 
 
ADJUVANT CHEMOTHERAPY 
 
Adjuvant chemotherapy consisting of multiple cycles of 
polychemotherapy, is well established as an important strategy 
for lowering the risk of breast cancer recurrence and improving 
survival. Multiple cycles of adjuvant chemotherapy, typically 
including anthracycline-based regimens, are recommended for 
the majority of patients with node-positive and higher risk 
node-negative tumors. Use of taxanes can contribute to 
significant improvement in outcomes, especially among women 
with node-positive breast cancer. 
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ADJUVANT HORMONAL THERAPY 
 
Tamoxifen is the agent most widely studied as adjuvant 
endocrine therapy for breast cancer. Tamoxifen administered 
for a duration of 5 years results in a 41% reduction in the 
annual rate of breast cancer recurrence and a 34% reduction in 
the annual death rate for women with ER-positive breast 
cancer.16 The optimal duration of tamoxifen therapy appears to 
be 5 years; extending tamoxifen therapy beyond 5 years in 
patients with no evidence of tumor recurrence has not led to 
further improvements in disease-free or overall survival.17 In 
the past 5 years, multiple clinical trials have examined the role 
of aromatase inhibitors (AIs) as adjuvant endocrine therapy for 
early breast cancer.  Tamoxifen acts by blocking estrogen 
stimulation of breast cancer cells, inhibiting both translocation 
and nuclear binding of the ER. This alters transcriptional and 
posttranscriptional events mediated by this receptor. Tamoxifen 
has agonistic, partial agonistic, or antagonistic effects, 
depending on the species, target, or end points that have been 
assessed. Although tamoxifen works by binding to the estrogen 
receptor, AIs function through inhibition of the aromatase 
enzyme that converts androgens into estrogens. The result is 
profound estrogen depletion in postmenopausal women. There 
is convincing data from a large randomized trial ATAC, that 
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aromatase inhibitors are fast replacing the anti-estrogens as the 
first line of management.19 In premenopausal women, ovarian 
ablation is achieved by surgical removal or with radiocastration 
or by Gonadotropin releasing hormone (GnRH) agonists.  
 
RADIOTHERAPY 
 
The role of radiotherapy in the adjuvant setting post 
mastectomy RT, is to reduce the locoregional recurrence. RT 
has also been used along with chemotherapy in the neoadjuvant 
setting. RT is a part of treatment in breast conservation therapy. 
Radiotherapy has been used at Cancer Institute for LABC prior 
to the availability of chemotherapy.20 
 
SUPRACLAVICULAR NODAL METASTASES 
 
At the turn of the twentieth century, Halstead, who 
devised the first truly radical mastectomy, had extended his 
operation to include dissection of the supra-clavicular region. 
He had performed supraclavicular dissection in 119 cases. None 
of those patients survived at 5 years.10 
 
Jackson et al, in 1966 did a retrospective analysis on the 
significance of supraclavicular lymph node metastases. One 
hundred and seventy four patients developed supraclavicular 
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lymph node metastases after radical mastectomy amongst 1,461 
early breast cancer patients. Eighty one of these patients 
developed these nodes as the first clinical evidence of 
recurrence. Evidence is presented from the literature and from 
this study that most of these metastases were present at the time 
of the mastectomy. It is suggested that, although they may be 
the only obvious metastases, supraclavicular nodes are usually 
evidence of widely spread disease. Of these 81 patients, 5% 
survived 10 years from the radical mastectomy. The findings of 
this study implied that ‘radical’ treatment did not alter their 
ultimate survival, but it did give greater palliation than simpler 
treatment.21 
 
Clinically, ipsilateral supraclavicular lymph node 
metastases (ISLM) in breast cancer can be classified into 2 
manifestations: metachronous and synchronous. Synchronous 
ISLM (T1-4, N3, M0) is stage IIIc. Metachronous ISLM is 
isolated supraclavicular lymph node relapse after curative 
treatment. Although both are featured with ipsilateral 
supraclavicular lymph node metastases they are two clinical 
entities needing to be addressed differently. 
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In 1997, Debois J et al, found that the data on 
supraclavicular lymph nodes are rather scarce, when compared 
with the literature on axillary nodes. He reviewed data on the 
incidence, the risk factors, the possibilities of the different 
adjuvant therapies in the prevention and the prognosis of a 
supraclavicular metastatic node in a patient with breast cancer. 
He concluded that the prognosis is rather dismal as 
supraclavicular nodes are mostly the prelude to new 
metastases.22 
 
PREDICTIVE FACTORS FOR ISLM: 
 
Shin Cheh Chen et al, analysed the predictive factors of 
supraclavicular lymph node metastases in breast carcinoma and 
found that the incidence of supraclavicular lymph node 
metastases was higher in the groups with >4 positive nodes and 
in those with axillary level II or III involved nodes. Selective 
use of comprehensive radiotherapy for these high-risk patients 
will achieve good loco regional control. In patients with 
axillary level I involved nodes and ≤4 positive nodes, the 
incidence was 4.4%. If level III nodes were involved, the rate of 
supraclavicular lymph node metastases was 15.1%.23 
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PROGNOSTIC FACTORS FOR ISLM: 
 
 Kirikuta et al, in his retrospective analysis of ISLM, found 
that the prognostic significance of supraclavicular lymph node 
involvement at primary diagnosis or as a relapse is similar, both 
have the same significance as the first distant relapse and are 
characterized by a poor prognosis. The axillary lymph node 
metastasis status and chemotherapy after occurrence of ISLM 
were independent prognostic predictors for metachronous 
ISLM, whilst primary tumor size and radiotherapy after 
diagnosis of ISLM (P = 0.022) were independent prognostic 
factors for synchronous ISLM .24 
 
SCL METASTASES AND TNM STAGING 
 
 Patient’s with breast cancer who present with 
supraclavicular metastases have a poor prognosis. The presence 
of supraclavicular metastases was one of the original signs of 
inoperability identified by Haagensen and Stout. In 1987, the 
International Union against Cancer/American Joint Committee 
on Cancer (AJCC) tumor-node-metastasis (TNM) staging 
system changed the classification of patients with 
supraclavicular metastases from N3 to M1 to reflect the poor 
prognosis of patients with this presentation.25 In 2001, Brito et 
al reported on a pooled analysis of three M.D. Anderson 
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Hospital protocols and found that patients with regional stage 
IV disease had better outcomes than patients with visceral stage 
IV disease. Clinical course and prognosis of patients with 
isolated supraclavicular metastases at presentation were similar 
to those of patients with stage III B locally advanced breast 
cancer.6 Thus, classifying supraclavicular node as a distant 
metastases may lead to undertreatment of patients. Hence in 
2003, the AJCC has further amended the staging classification 
to include patients with supraclavicular metastases at diagnosis 
in the IIIC category.14 
 
COMBINED MODALITY THERAPY FOR ISLM: 
 
 Eugene H. Huang did a retrospective analysis of 71 
patients with ISLM at presentation. Radiotherapy achieved 
excellent locoregional control after surgery for patients with 
ISLM, who achieved a complete response of the supraclavicular 
disease after neoadjuvant chemotherapy. For patients who 
achieved a complete response of the supraclavicular  disease by 
physical examination, ultrasonography of the SCV fossa may 
help assess the risk of disease recurrence.26 
 
Most of the patients who present with LABC and ISLM 
have very poor survival with standard treatment modalities, and 
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over the past 20 years combined modality therapy has been 
used to improve local and systemic control. Uncontrolled trials 
strongly suggest that patients with any stage of locally 
advanced breast cancer achieve high response rates after 
induction chemotherapy. Most of these patients can be rendered 
disease free after combined modality therapy, and their disease-
free and overall survival rates appear to be improved when 
compared with historical controls. 
 
Pergolizzi et al, conducted a prospective nonrandomized 
trial in order to evaluate the role of radiotherapy (RT) with 
"radical dose" to the supraclavicular fossa. He compared 
systemic therapy alone (arm A) to integrated and aggressive 
treatment - systemic therapy plus radiotherapy (arm B). In 
comparison to arm A, patients in arm B had longer median  
time to progression of 20 months and better median overall 
survival of 41 months. These data demonstrated that a better 
event free survival could be achieved in patients with ISLM 
submitted to induction CT and radical irradiation. This also 
translated into a longer survival although this did not achieve 
statistical significance. He also stressed the importance of local 
control by RT.27 
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Lena Mario et al, assessed the efficacy of two combined 
modality approaches (chemotherapy plus radiotherapy Vs 
chemotherapy plus mastectomy) in a total of 132 women with 
locally advanced breast cancer. There was no significant 
difference between the two treatment groups in terms of 
patterns of treatment failure, median duration of response, and 
total survival. Treatment was not influenced by menopausal or 
estrogen receptor status. The results of the study failed to 
indicate that surgery per se improved the overall results, 
including local control, over radiotherapy in a combined 
modality setting.28 
 
Gardin et al analysed the prognostic factors in patients 
homogenously treated with combined modality approach 
(chemotherapy, RT and surgery). Univariate analysis showed 
that age, receptor status and clinical and pathological response 
to primary chemotherapy did not appear to influence treatment 
outcome significantly, whereas stage, presence of inflammatory 
disease and number of involved nodes had a significant impact 
on both overall survival and progression free survival.29 
 
Sanchez ER et al assessed the factors affecting the 
outcome of patients presenting with LABC with combined 
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modality approach of treatment. In univariate analysis, clinical 
stage, pathological stage, oestrogen receptor status and type of 
therapy were significant predictors for disease-free survival 
(DFS) and overall survival (OS). However, in a multivariate 
analysis, only clinical stage was a significant predictor for both 
DFS and OS, while ER status was a significant predictor for 
OS.30 
 
In patients presenting with ISLM as the only site of 
metastases at diagnosis, who receive treatment with combined 
modality approach, it was found that, nearly two-thirds of the 
patients developed a recurrence by 5 years. Loco-regional 
recurrence was the site of first recurrence in one-third of the 
patients by 5 years.30 
 
Survival benefit of neck dissection for patients with breast 
cancer with supraclavicular lymph node metastasis was 
assessed in a study by Shin Chen et al from Taiwan. Neck 
dissection was defined as curative intent to remove all nodes 
and soft tissue in neck level IV and part of III and V. Forty-nine 
in 127 SLNM patients had received neck dissection. The 5, 10 
years OS for those who received neck dissection or not were 
30.6%, 16.1%, and 14.9%, 4.7% respectively which was 
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statistically significant. In multivariate analysis, neck 
dissection, disease-free interval and hormonal therapy were 
independent prognostic factor for survival.31 
 
Shin-Cheh Chen et al, performed a study to analyze the 
survival of breast cancer patients with isolated supraclavicular 
lymph node metastasis and assess whether ISLM is distant 
metastasis or not. The survival after ISLM was compared with 
that of  patients who developed local recurrences and  who had 
distant metastasis. The 5-year overall survival (OS) rates after 
ISLM, local relapse, and distant metastasis were 33.6%, 34.9%, 
and 9.1% respectively. Good neck control either by surgery or 
chemotherapy achieved better survival.23 
 
There still is debate as to whether breast carcinoma 
patients with isolated supraclavicular recurrence should be 
considered to be patients with disseminated disease or patients 
for whom aggressive treatment with curative intent is justified. 
 Maurice et al, followed up of 42 patients with isolated 
supraclavicular recurrence, without other sites of distant 
disease. Although complete remission can be obtained in most 
patients with isolated supraclavicular recurrence, the prognosis 
for these patients is poor. The distant disease–free survival rate 
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was  better for the 25 patients who underwent radiotherapy as 
part of the treatment for supraclavicular recurrence than it was 
for the 17 patients who did not receive radiotherapy (P _ 0.06); 
Patients who had received axillary and supraclavicular 
radiotherapy as part of treatment had better distant disease free 
survival. Involved field radiotherapy appears to play an 
important role in the treatment of supraclavicular recurrence 
and may improve the distant recurrence–free survival.32 
 
Ivo A. Olivotto conducted a retrospective analysis and 
compared long-term survival in a population-based cohort of 
patients with isolated supraclavicular metastases (nodal-M1) to 
outcomes of patients with stage IIIB or M1 (other) disease at 
presentation. A total of 51 (1%) had supraclavicular but no 
other metastases. The median overall survival durations were 
2.4 years for supraclavicular cases. A small proportion of M1 
(other) patients ( 2%), 9% of IIIB patients, and 13% of the 
patients presenting with supraclavicular lymph node metastases 
alone survived longer than 20 years from diagnosis. 
 
A limitation of the study is that the majority of patients 
with supraclavicular metastases had the diagnosis made 
clinically. The 5 year OS for stage IIIB, stage IIIC, stage IV 
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was 43%, 33% and 15%  respectively. Breast cancer–specific 
survival at 20 years was 24.1% for nodal-M1 cases, 30.2% for 
IIIB cases and 3.9% for M1 (other) cases (P <.0005). Patients 
with supraclavicular metastases at diagnosis have significantly 
better outcomes than patients with M1 (other) disease and 
overall survival similar to patients with IIIB disease.5 
 
Brito et al, in 2001 reviewed the records of all 598 
patients with LABC who were treated on three prospective 
trials of combined-modality therapy for LABC at M.D. 
Anderson Cancer Center between 1974 and 1991. He identified 
70 patients who presented with ipsilateral supraclavicular 
metastases but no evidence of other distant metastases. The 
median patient age was 49 years (range, 24 to 78 years). The 
overall response rate (complete response plus partial response) 
to neoadjuvant chemotherapy was 89%. With a median follow-
up duration of 11.6 years (range, 4.8 to 22.6 years), the local-
regional control rate was 81%. The median duration of survival 
was 3.5 years. The median duration of disease-free survival was 
1.9 years. The probabilities of survival to 5 and 10 years were 
41% and 31%, respectively. The 5 and 10year disease-free 
survival rates were 34% and 32% respectively. More 
importantly, with a median follow-up of 11.6 years and a 
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maximum follow-up of 22.6 years,  results indicated that 
approximately 32% of these patients will remain alive and 
disease-free at 10 years. The overall survival curve was 
significantly better than that of patients with metastatic breast 
cancer. Patients with ipsilateral supraclavicular metastases but 
no other evidence of distant metastases warrant therapy 
administered with curative intent, i.e, combined-modality 
therapy consisting of chemotherapy, surgery and radiotherapy.6 
 
Alexandros Adravanis et al, analysed the results of 
multidisciplinary therapy of Locally far-advanced with fixed 
perioperative sequence of epirubicin, vinorelbine and 
fluorouracil chemotherapy, surgery, and radiotherapy. Patients 
with stage IIIB or IIIC had more pathological responses than 
Inflammatory breast cancer patients (p = .005). No difference in 
the probability of recurrence and death was found between 
stage IIIB/IIIC. Clinically responding patients had longer 
Recurrence free survival and OS (p = .001 and p = .004), 
respectively.33 
 
PET scan is a functional imaging that has gained 
widespread acceptance in diagnosis, staging and management 
of variety of malignancies including breast cancer. The level of 
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uptake is semiquantified and reported as Standardised Uptake 
Value (SUV). It is ideal to use PET scan for initial staging 
(axillary, internal mammary, supraclavicular and mediastinal 
nodes), recurrences in asymptomatic patients and re-staging 
patients with locoregional recurrences. 
 
Abraham et al, conducted a prospective trial in patients 
with SCL metastases by treating them with high dose 
chemotherapy and peripheral stem cell transplantation. He 
concluded that the long term outcome was better in patients 
receiving high dose chemotherapy; whether this result is 
superior to that achieved with standard therapy alone remains to 
be confirmed in randomized trials.34 
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RESULTS 
 
 
 
INCIDENCE 
 
In our study, the incidence of isolated supraclavicular 
nodal metastasis at presentation in patients with carcinoma 
breast was 1.07%.  
 
PATIENT CHARACTERISTICS: 
 In our study, the median patient age was 45 years (range 
29 – 75 years). (Figure 1) 
[ 
Figure 1 
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MENOPAUSAL STATUS 
 
18 patients (30%) were premenopausal and 42 patients 
(70%) were postmenopausal. (Figure 2) 
 
 
 
Figure 2 
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RECEPTOR STATUS  
 
Out of the total 60 patients, estrogen receptor status was 
available in 54 patients and unknown in 6 patients. (Figure 3) 
 
Figure 3 
 
 
Out of the total 60 patients, progesterone receptor status 
was available in 53 patients and unknown in 7 patients. (Figure 
4) 
Figure 4 
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METHOD OF DIAGNOSIS OF SCL NODE: 
 
In our study, 40 patients underwent FNAC of the 
supraclavicular node and 20 patients underwent node biopsy. 
(Figure 5) 
 
 
 
 
Figure 5 
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HISTOPATHOLOGICAL GRADE 
 
 
Out of the total 60 patients, 41 patients (68.3%) had 
Grade 3 tumor, 18 patients (30%) had grade 2 tumor. (Figure 6) 
 
 
 
Figure 6 
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TUMOR STATUS 
 
 
34 patients (56.7%) belonged to T4 tumor status, 17 
patients (28.3%) belonged to T3 and 9 patients (15%) belonged 
to T2 tumor status. (Figure 6) 
 
 
Figure 7 
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TREATMENT MODALITY 
 
 
Majority of the patients (88.3%) received concurrent 
chemo radiotherapy. One patient received radiotherapy alone. 
Six patients  (10%) received chemotherapy alone. (Figure 8) 
 
 
Figure 8 
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CLINICAL RESPONSE TO TREATMENT 
 
 
The overall response rate (complete plus partial response) 
to chemoradiotherapy was 88%. In our study, 57% of patients 
experienced clinical complete response, 31.7% had a partial 
response, 6.7% had stable disease.  5% of the patients had 
disease progression during treatment. (Figure 9) 
 
Figure 9 
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The following chemotherapy regimens were used. (Figure 10) 
 
Endoxan 2 3.4% 
CMF 17 28.3% 
FAC 33 55.9% 
FEC 3 5.1% 
TE 3 5.1% 
VP16 1 1.7% 
 
Figure 10 
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HORMONAL THERAPY 
 
Fifty percent of the patients received Hormonal therapy 
either in the form of Tamoxifen or Letrozole. Six patients 
(10%) had bilateral salpingo-oopherectomy. (Figure 11) 
 
 
Figure 11 
 
 
 
 
 
 
 
47 
 
RELAPSE RATES 
 
 
In our study, 43 patients (71.7%) had relapse of tumor, 
one patient had disease progression during treatment and 16 
patients (26.7%) were disease free till the last date of follow up. 
(Figure 12) 
 
Figure 12 
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RECURRENCE PATTERNS 
 
The site of recurrence among the 43 patients who relapsed 
were as follows: Local – 5 (8.3%), Regional – 1 (1.7%), Distant 
– 36 (60%), Local + distant – 1 (1.7%). (Figure 13) 
 
Figure 13 
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STATISTICAL ANALYSIS 
 
 
UNIVARIATE ANALYSIS 
 
VARIABLE P VALUE 
Age 0.52 
Menopausal status 0.81 
T stage 0.04 
ER status 0.003 
Treatment modality 0.03 
Clinical response 0.001 
Hormonal therapy 0.001 
Histopathological grade 0.61 
Adriamycin based chemotherapy 0.32 
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MULTIVARIATE ANALYSIS 
 
VARIABLE 
HAZARD 
RATIO 
CONFIDENCE 
INTERVAL 
SIGNIFICANCE 
P VALUE 
T stage 8.27 1.01 – 67.43 0.05 
Menopausal 
status 
8.00 1.35 – 47.29 0.08 
Estrogen receptor 
status 
4.7 0.73 – 30.37 0.10 
Histopathological 
grade 
0.45 0.64 – 14.7 0.80 
Treatment 
modality 
0.36 0.10 – 1.29 0.12 
Clinical 
response 
3.73 1.26 – 11.05 0.018 
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SURVIVAL CURVE 
 
OVERALL SURVIVAL & DISEASE FREE SURVIVAL 
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The five year overall survival and disease free survival 
were 31.3% and 11.7% respectively. 
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DISCUSSION 
 
 
 
Breast cancer is today the most common cancer amongst 
the  women of developed countries. Of late, the incidence of 
breast cancer has increased in our country too and it has 
become the most common cancer amongst women of the four 
metropolitan cities of our country. Most patients present with 
locally advanced breast cancer and as metastatic breast cancer. 
Advances in investigative modalities and newer treatment 
options combined with screening have decreased the mortality 
due to the disease. The current treatment regimens have 
improved the survival of LABC. 
 
Isolated ipsilateral supraclavicular lymph nodal 
metastases at presentation is a rare but important occurrence in 
breast cancer. The presence of supraclavicular nodal metastases 
was earlier considered as a predecessor to distant metastases. 
Haagenson et al, achieved no 5-year clinical cures among 
patients with supraclavicular involvement.15 
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In our study, the incidence of ipsilateral supraclavicular 
nodal metastases at presentation was 1.07%. Fifty percent of the 
patients in our study group were above 45 years. Most of them 
presented with locally advanced primary. About 56.7% of 
patients had T4 disease at presentation.  
 
Most of the patients (88%) in our study received 
concurrent chemoradiotherapy. At the Cancer Institute (WIA) 
Chennai, concurrent chemoradiotherapy began way back in the 
1970’s, when radiotherapy was given to the large tumors to 
increase the chance of surgery. With the advent of 
chemotherapy, the Institute started using both chemotherapy 
and radiotherapy in a concurrent manner in LABC.  
 
The objective in combining radiotherapy and 
chemotherapy in LABC was the early introduction of 
chemotherapy. The two modalities could be synergistic in 
reducing the tumor and nodal volume, in addition to the 
chemotherapeutic impact on micrometastases.  
 
The results of our protocol concurrent chemoradiotherapy 
in the setting of LABC have demonstrated a significant increase 
in tumor sterility (complete pathological response) and nodal 
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down staging. This concept has also been applied in patients 
presenting with ipsilateral supraclavicular metastases.36  
 
The intent of treatment for patients with ipsilateral 
supraclavicular nodal metastases at presentation is curative. 
Patients who completed the concurrent chemoradiation were 
assessed for the response to treatment at the end of therapy.  
 
The overall response rate (complete plus partial response) 
to chemoradiotherapy was 88%, which is comparable with one 
of the largest series published by Brito et al in 2001,6 in which 
he quoted a overall response rate of 89%. In our study, 57% of 
patients experienced clinical complete response, 31.7% had a 
partial response, 6.7% had stable disease.  5% of the patients 
had disease progression during treatment.  
 
The most common chemotherapeutic regimen used was 
FAC (56%).  Sixty-six percent of the patients received 
adriamycin based chemotherapy.  
 
The factors that we thought, which could affect the 
response to treatment were age, T stage, grade, ER/PR status 
and combined modality of therapy (chemoradiation). But on 
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analyzing our results we found that  the only factor which had a 
bearing upon the response to treatment was the combined 
modality of therapy (p= <0.05).  
 
Surgery was performed only in nine patients (15%). The 
median interval between the completion of chemoradiation and 
surgery was 6 months. Out of the 9 patients who underwent 
surgery, 7 had modified radical mastectomy, 2 patients 
underwent total mastectomy since axillary dissection could not 
be performed due to the nodes being stuck to the axillary vein. 
Out of the nine patients who underwent surgery only two had 
complete pathological response.  
 
Since 2005, at our institute, we have been recommending 
the option of surgery after the completion of concurrent 
chemoradiation. Patients who completed chemoradiation were 
observed for a period of 6 months and a metastatic workup was 
done at the end of 6 months. If  the patient showed no evidence 
of distant metastases, these patients were offered surgery. The 
rationale being, patients with isolated supraclavicular 
metastases most commonly relapse with distant metastases. In 
our study, the low percentage (15%) of patients who underwent 
surgery, can be explained by the fact that many patients refused 
surgery after completion of chemoradiation. 
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In our study, univariate analysis showed that performing 
surgery was not a significant factor which affected overall 
survival (p value = 0.33). This result should be inferred with 
caution, since only a small percentage of patients underwent 
surgery to achieve statistical significance. 
 
Hormonal therapy was given based upon the ER/PR 
status. Hormonal therapy included tamoxifen in 57 %, 
Letrozole in 33% and ovarian ablation in 10% of patients.  
 
The median follow up duration of our study was 30 
months (range 5 – 77 months). 
 
On follow up, the median time to relapse was 12 months. 
Forty-three patients (72%) relapsed during the follow up period. 
The most common site of relapse was distant metastases 
constituting about 83%. The most common site of distant 
metastases being lungs in 44.4%. Out of the 43 patients who 
relapsed after initial treatment, 19 patients (44%) received 
treatment for the relapse and the remaining 24 patients (56%) 
who relapsed were treated with best supportive care. Most of 
the patients (69%) received chemotherapy at relapse.  
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Univariate analysis showed that the age, menopausal 
status, histopathogical grade, surgery and type of chemotherapy 
did not appear to influence the treatment outcomes 
significantly, whereas the T stage (p value = 0.04), ER/PR 
status (p value = 0.003), combined modality of treatment (p 
value = 0.03), clinical response to treatment (p value = 0.003) 
and hormonal therapy (p value = 0.001) had an impact on 
overall survival.  
 
Multivariate analysis showed that only, T stage (p value = 
0.04) and clinical response to treatment (p value = 0.02) had a 
statistically significant impact on the overall survival. The 
combined modality of treatment, chemoradiotherapy which was 
significant in univariate analysis, lost it’s significance in the 
multivariate analysis the results of which are similar to that of 
other studies. 
   
In our study, patients with T4 tumor status had 8 fold 
increased risk of disease recurrence or death than T2 tumor. 
Patients who achieved complete clinical response to 
chemoradiation had a 3 fold decreased  risk of disease 
recurrence or death. 
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The 5 year overall survival in our study was 31.3%, which 
is almost similar to that of the study done by Brito et al (41%).6  
In our study, the median overall survival duration was 38 
months (range 5 – 77 months). Our study demonstrated that a 
significant percent of patients    (26.7%), may be long term 
survivors.  
 
In summary, we suggest that infraclavicular and 
supraclavicular lymph nodes are part of a continuum in the 
regional lymph node drainage of the breast. Axillary lymph 
node levels 1, 2, and 3 and the infraclavicular and 
supraclavicular lymph nodes are not separated on the basis of 
functional differences. They are separated according to 
arbitrary anatomic boundaries and gradual worsening of 
prognosis when treatment consists of chemotherapy alone or 
radiation therapy alone.  
 
It therefore seems appropriate that, patients with isolated 
ipsilateral supraclavicular nodal metastases at presentation 
should be treated with  radical intent. Treatment should include 
concurrent chemoradiotherapy, followed by a definitive 
treatment to the local area if rendered operable by a modified 
radical mastectomy. 
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CONCLUSION 
 
 
 
 
Patients with breast cancer who present with isolated 
ipsilateral supraclavicular nodal metastases, though previously 
thought to be a subset of patients with poor prognosis and a 
predecessor of distant metastases, need definitive treatment 
with multidisciplinary approach. 
 
In our Institute, we have been practising concurrent  
chemotherapy and radiotherapy followed by surgery if rendered 
operable. The 2003 revision of the AJCC breast cancer TNM 
staging system has appropriately reclassified patients presenting 
with supraclavicular metastases from M1 to a new category 
IIIC.   
        In our study, the incidence of isolated supraclavicular 
nodal metastases at presentation in patients with carcinoma 
breast was 1.07%. 
In our study, the 5 year overall survival and disease free 
survival were 31.3% and 11.7% respectively. The overall 
response rate (complete plus partial response) to 
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chemoradiotherapy was 88%. About 72% of patients relapsed 
after the completion of chemoradiotherapy. The median time to 
relapse was 12 months.  
 
The most common site of relapse was distant metastases 
constituting about 83%. The most common site of distant 
metastases was lungs (44%). The median follow up duration 
was 30 months (range 5 – 77 months). 
 
The T stage and the clinical response to concurrent 
chemoradiation had a significant impact on the overall survival 
in multivariate analysis.  
 
Patients with ipsilateral supraclavicular nodal metastases 
at presentation, but with no other evidence of distant metastases 
have outcomes more similar to stage IIIB, rather than stage IV. 
Therapeutic nihilism and sequential palliative interventions 
alone may well be insufficient unless the patient’s performance 
status indicates that radical treatment will not be tolerated.  
 
The intent of treatment in this subset of patients, therefore 
should be curative. The definitive multidisciplinary treatment 
which combines chemotherapy, radiotherapy and surgery has to 
be the standard of care and will go a long way in improving the 
treatment outcomes for these patients.    
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